Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cybin (CYBN) has announced positive preclinical data from a study of its proprietary deuterated dimethyltryptamine (DMT) molecule, CYB004
  • When inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled DMT, including a longer duration of action, and improved bioavailability
  • CEO Doug Drysdale sat down with Dave Jackson to discuss the news
  • Inhaled CYB004 is being developed to overcome the limitations of IV DMT and become an important treatment option for anxiety disorders
  • Cybin is a Canadian biopharmaceutical company
  • Cybin Inc. (CYBN) opened trading at C$0.93 per share

Cybin (CYBN) has announced positive preclinical data from a pharmacokinetic study of its proprietary deuterated dimethyltryptamine (DMT) molecule, CYB004.

When inhaled CYB004 demonstrated significant advantages over both IV DMT and inhaled DMT, including a longer duration of action, and improved bioavailability.

CEO Doug Drysdale sat down with Dave Jackson to discuss the news.

“In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues. However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability. CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic. As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians.” 

Cybin is a Canadian biopharmaceutical company on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. 

Cybin Inc. (CYBN) opened trading at C$0.93 per share.

More From The Market Herald

" Top 5 Stories of the Week: Empower Clinics (CSE:CBDT), Eat Well Group (CSE:EWG), Tocvan Ventures (CSE:TOC), Mullen Group (TSX:MTL), EasTower Wireless (TSXV:ESTW)

With inflation reaching 7.7 per cent in May, the highest in 40 years, recessionary fears are running rampant.

" @ the Bell: Summer blues for TSX, Wall Street sees worst half since 1970

On the last day before the Canada Day long weekend, the TSX finished lower by triple digits in broad-based decline as commodity prices

" Top 5 Stories of the Week: Baselode Energy Corp. (TSXV:FIND), Green River Gold (CSE:CCR), Mantaro Precious Metals (TSXV:MNTR), Granite Creek Copper (TSXV:GCX), Tocvan Ventures (CSE:TOC)

As the first half of 2022 draws to an end, the news about inflation and the stock market performance has not given investors

" This Company is Discovering More Gold in Ecuador, with its Copper Story Just Starting

While gold production in countries such as Peru, — which is South America’s leading gold producer — Brazil, Colombia, Bolivia and Argentina dominate